Technical Analysis for CYTK - Cytokinetics, Incorporated

Grade Last Price % Change Price Change
grade D 7.03 0.14% 0.01
CYTK closed down 0.28 percent on Thursday, January 17, 2019, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CYTK trend table...

Date Alert Name Type % Chg
Jan 17 50 DMA Resistance Bearish 0.14%
Jan 17 NR7 Range Contraction 0.14%
Jan 17 Wide Bands Range Expansion 0.14%
Jan 16 50 DMA Resistance Bearish -0.14%
Jan 16 180 Bearish Setup Bearish Swing Setup -0.14%
Jan 16 Wide Bands Range Expansion -0.14%
Jan 15 20 DMA Support Bullish 0.14%
Jan 15 NR7 Range Contraction 0.14%
Jan 15 Wide Bands Range Expansion 0.14%
Jan 14 Fell Below 50 DMA Bearish 0.72%

Older signals for CYTK ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Is CYTK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 10.26
52 Week Low 5.9
Average Volume 403,204
200-Day Moving Average 7.8611
50-Day Moving Average 7.1142
20-Day Moving Average 6.7895
10-Day Moving Average 7.216
Average True Range 0.4261
ADX 19.59
+DI 24.1397
-DI 17.8877
Chandelier Exit (Long, 3 ATRs ) 6.6617
Chandelier Exit (Short, 3 ATRs ) 7.1783
Upper Bollinger Band 7.8094
Lower Bollinger Band 5.7696
Percent B (%b) 0.61
BandWidth 30.043449
MACD Line 0.0023
MACD Signal Line -0.0327
MACD Histogram 0.0349
Fundamentals Value
Market Cap 376.74 Million
Num Shares 53.7 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -20.65
Price-to-Sales 6.91
Price-to-Book 3.91
PEG Ratio -0.34
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.36
Resistance 3 (R3) 7.37 7.27 7.30
Resistance 2 (R2) 7.27 7.19 7.27 7.28
Resistance 1 (R1) 7.15 7.13 7.21 7.13 7.26
Pivot Point 7.05 7.05 7.08 7.04 7.05
Support 1 (S1) 6.92 6.96 6.99 6.91 6.78
Support 2 (S2) 6.82 6.91 6.82 6.76
Support 3 (S3) 6.70 6.82 6.74
Support 4 (S4) 6.68